BR132017004005E2 - use of pharmaceutical composition for treatment of poikiloderma cutaneous erythema - Google Patents
use of pharmaceutical composition for treatment of poikiloderma cutaneous erythemaInfo
- Publication number
- BR132017004005E2 BR132017004005E2 BR132017004005A BR132017004005A BR132017004005E2 BR 132017004005 E2 BR132017004005 E2 BR 132017004005E2 BR 132017004005 A BR132017004005 A BR 132017004005A BR 132017004005 A BR132017004005 A BR 132017004005A BR 132017004005 E2 BR132017004005 E2 BR 132017004005E2
- Authority
- BR
- Brazil
- Prior art keywords
- poikiloderma
- treatment
- compounds
- adrenergic receptor
- similar
- Prior art date
Links
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
uso de composição farmacêutica para tratamento do eritema cutâneo das poiquilodermias. o presente certificado de adição de invenção pertence ao setor tecnológico da indústria farmacêutica e se refere, mais especificamente, a um maior detalhamento nas composições de segundo uso destinadas ao tratamento das telangiectasias responsáveis pelo eritema das lesões de poiquilodermia de civatte. esse detalhamento revela a gama de compostos da mesma classe farmacológica dos agonistas dos receptores a-adrenérgicos, pelo fato de apresentarem efeitos clínicos similares em outros eritemas como a rosácea e, portanto, podendo também ser utilizados no tratamento da poiquilodermia de civatte de forma análoga ao agonista dos receptores a-adrenérgicos brimonidina, referido na invenção original. uma vez que tal invenção reivindica o uso de todos os compostos do mesmo grupo farmacológico dos agonistas dos receptores a-adrenérgicos no tratamento dessa afecção, tal certificado de adição apenas visa melhor detalhar o grupo de compostos farmacológicos agonistas desses receptores e sua funcionalidade comprovadamente similar a da briomidina anteriormente revelada.use of pharmaceutical composition to treat poikiloderma cutaneous erythema. The present Certificate of Addition of Invention belongs to the technological sector of the pharmaceutical industry and refers more specifically to further details of second-use compositions for the treatment of telangiectasias responsible for the erythema of civatte poikiloderma lesions. This detail reveals the range of compounds of the same pharmacological class as α-adrenergic receptor agonists, as they have similar clinical effects in other erythemas such as rosacea and, therefore, can also be used in the treatment of civatte poikiloderma similar to α-adrenergic receptor agonist brimonidine referred to in the original invention. Since such an invention claims the use of all compounds of the same pharmacological group as Î ± -adrenergic receptor agonists in the treatment of such disorder, such a certificate of purpose is intended only to further detail the group of agonist pharmacological compounds of such receptors and their functionality demonstrably similar to those of a drug. of the previously disclosed bromomidine.
Priority Applications (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| BR132017004005A BR132017004005E2 (en) | 2017-02-24 | 2017-02-24 | use of pharmaceutical composition for treatment of poikiloderma cutaneous erythema |
| EP17769197.9A EP3434271B1 (en) | 2016-03-22 | 2017-03-22 | Use of pharmaceutical composition for the treatment of poikiloderma of civatte |
| PCT/BR2017/050070 WO2017161432A1 (en) | 2016-03-22 | 2017-03-22 | Use of pharmaceutical composition for the treatment of skin erythema in poikilodermas |
| US16/087,580 US10617688B2 (en) | 2016-03-22 | 2017-03-22 | Use of pharmaceutical composition for the treatment of skin erythema in poikilodermas |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| BR132017004005A BR132017004005E2 (en) | 2017-02-24 | 2017-02-24 | use of pharmaceutical composition for treatment of poikiloderma cutaneous erythema |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR132017004005E2 true BR132017004005E2 (en) | 2017-09-26 |
Family
ID=62044103
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR132017004005A BR132017004005E2 (en) | 2016-03-22 | 2017-02-24 | use of pharmaceutical composition for treatment of poikiloderma cutaneous erythema |
Country Status (1)
| Country | Link |
|---|---|
| BR (1) | BR132017004005E2 (en) |
-
2017
- 2017-02-24 BR BR132017004005A patent/BR132017004005E2/en active Search and Examination
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112018075734A2 (en) | compound, pharmaceutical composition, method of treating a patient with a disease or condition mediated at least in part by fxr, and use of a compound. | |
| CY1122966T1 (en) | 5-BROMO-2,6-DI-(1H-PYRAZOL-1-YL)PYRIMIDIN-4-AMINE FOR USE IN THE THERAPEUTIC TREATMENT OF CANCER | |
| BR112015019794A8 (en) | COMPOUND, PHARMACEUTICAL COMPOSITION, SPHINGOSINE-1-PHOSPHATE RECEPTOR AGONIST, AND, USE OF A COMPOUND | |
| BR112018075992A2 (en) | pyridines substituted as dnmt1 inhibitors | |
| BR112018015273A2 (en) | benzimidazole derivatives as ror-gamma modulators | |
| EA201891191A1 (en) | 2-SUBSTITUTED HINAZOLIN COMPOUNDS CONTAINING A SUBSTITUTED HETEROCYCLIC GROUP AND METHODS OF THEIR APPLICATION | |
| BR112018000212A2 (en) | combined use of anti pd-1 and anti m-csf antibodies in cancer treatment | |
| EA201691151A1 (en) | CONNECTIONS FOR THE TREATMENT OF PATIENTS WITH ROS1-MUTANT CANCER CELLS | |
| CR20160203A (en) | BRUTON TYPEOSIN CINASE INHIBITORS | |
| BR112015026830A2 (en) | compound, pharmaceutical composition, use of a compound, method for prophylaxis or treatment of a disease state or condition | |
| BR112015023948A2 (en) | compound of formula (i), pharmaceutical composition, method for treating and / or preventing a proliferative disease and for inhibiting or differentiating growth of a cancer stem cell | |
| BR112017023764A2 (en) | starch substituted cyclohexane derivatives | |
| EA201000091A1 (en) | DERIVATIVES OF MORFOLINOPYRIMIDINE USED IN DISEASES ASSOCIATED WITH mTOR KINASE AND / OR PI3K | |
| BR112015029972A2 (en) | compound, pharmaceutical composition, process for preparing a pharmaceutical composition, method for treating a disease, compounding and using a compound | |
| CY1121554T1 (en) | PRODUCER OF PYRANOCHROMENYL-PHENOLIS, AND PHARMACEUTICAL COMPOSITION FOR TREATMENT OF METABOLIC SYNDROME OR INFLAMMATORY DISEASE | |
| BR112015024073A2 (en) | 3-ACETYLAMINE-1- DERIVATIVES (PHENYL-HETEROARYL-AMINOCARBONY OR PHENYL-HETEROARYL CARBONYLAMINE) BENZENE FOR TREATMENT OF HYPERPROLIFERATIVE DISEASES | |
| EA201591686A1 (en) | PYRIDINYL AND CONDENSED PYRIDINYL DERIVATIVES OF TRIAZOLONE | |
| AR096892A1 (en) | A PHARMACEUTICAL COMBINATION FOR THE TREATMENT OF MELANOMA | |
| BR112016021648A2 (en) | new compounds | |
| BR112015019039A8 (en) | fluorinated integrin antagonist compounds, a pharmaceutical composition comprising said compounds and their use to treat or prevent an av integrin mediated disease or condition | |
| EA201590183A1 (en) | AZAINDOL DERIVATIVES PERFORMING AS PI3K INHIBITORS | |
| ECSP12011703A (en) | PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF CANCER AND OTHER DISEASES OR DISORDERS | |
| BR112019004168A2 (en) | crystalline hydrate, pharmaceutical composition, and method of treating a disease or condition | |
| BR112017026272A2 (en) | compound, pharmaceutical composition, method for treating a muscarinic m1 receptor-related disorder and use of the compound | |
| BR112022009086A2 (en) | EGFR ALLOSTERIC INHIBITORS AND METHODS OF USE THEREOF |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B03B | Publication of an application: publication anticipated [chapter 3.2 patent gazette] | ||
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
| B15G | Petition not considered as such [chapter 15.7 patent gazette] | ||
| B07E | Notice of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] |
Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI |
|
| B11Q | Dismissal: the certificate of addition was not accessory to any patent, or a patent which was nominated accessory and no longer exists | ||
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] |
Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS. |
|
| B07B | Technical examination (opinion): publication cancelled [chapter 7.2 patent gazette] | ||
| B11T | Dismissal: dismissal of application maintained |